Annexin Pharmaceuticals AB (publ)

Research Annexin Pharmaceuticals AB (publ) (Q910) on Bullrun: market cap EUR 7.70M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerQ910
• ExchangeF
• CountrySweden
• SectorHealthcare
• IndustryBiotechnology
• CurrencyEUR
• Market capEUR 7.70M
• Financial periodQ1 2026
• Net income-EUR 10.52M
• Free cash flow-EUR 10.33M

Valuation Snapshot

latest market cap is EUR 7.70M.

About Annexin Pharmaceuticals AB (publ)

Annexin Pharmaceuticals AB (publ), a clinical stage biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases. It develops ANXV, a human recombinant protein and Annexin A5, natural protein that protects and repairs cells, as well as counteract unwanted inflammatory and immune cell reactions that is in phase 2 clinical phase for the treatment of ophthalmology, oncology, sickle cell disease, and cardiovascular disease.

Frequently asked questions

What is Annexin Pharmaceuticals AB (publ)'s market cap?

Annexin Pharmaceuticals AB (publ)'s market capitalization is EUR 7.70M.

What does Annexin Pharmaceuticals AB (publ) do?

Annexin Pharmaceuticals AB (publ), a clinical stage biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases.